ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

ImmunityBio (NASDAQ:IBRX) is expected to be releasing its earnings data before the market opens on Tuesday, March 18th. Analysts expect ImmunityBio to post earnings of ($0.26) per share and revenue of $9.51 million for the quarter.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Trading Down 1.0 %

Shares of IBRX stock opened at $2.87 on Friday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -3.12 and a beta of 0.82. The stock has a fifty day simple moving average of $3.08 and a two-hundred day simple moving average of $3.66.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IBRX. BTIG Research began coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Thursday. Finally, D. Boral Capital reissued a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a research report on Thursday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, ImmunityBio presently has a consensus rating of “Buy” and an average price target of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.